Clinical trials: Patients With Heart Failure With Reduced Ejection Fraction - HFrEF
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
This study will evaluate whether adding Yiqi Fumai lyophilized injection to stable guideline-directed treatment improves symptoms, physical limitations, and NT-proBNP in adults with stable chronic heart failure caused by coronary…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
- Trial name
- NCT07803471
- Testing
- Yiqi Fumai Lyophilized Injection(YQFM), Stable Guideline-Directed Medical Therapy
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- China Academy of Chinese Medical Sciences
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent
Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment
With the aging of society, the use of cardiac pacing in patients with irreversible bradycardia is increasingly widespread. As early as the 1950s, right ventricular pacing (RVP) began to be used in patients with atrioventricular…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation, Persistent, Sick Sinus Syndrome, Atrioventricular Block
- Trial name
- NCT05575557
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai 10th People's Hospital
Heart Failure With Reduced Ejection Fraction
Respiratory Sinus Arrhythmia (RSA) Pacing Post-CABG Surgery in Patients With HFrEF
The goal of this clinical trial is to test a new type of pacemaker in heart failure patients following a heart bypass operation.
- Trial name
- RSA-PACE (NCT06359938)
- Testing
- Atrial pacing with respiratory sinus arrhythmia (RSA) variability, Monotonic right atrial overdrive pacing
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Ceryx Medical Ltd
Heart Failure With Reduced Ejection Fraction
Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients
Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin…
- Trial name
- NCT06382571
- Testing
- Renin-Angiotensin System Inhibitor
- Volunteers
- 396 people
- Sponsor
- Chulalongkorn University
Assessment of the RV Function in Patients With Heart Faliure
Right Ventricular Function in Heart Failure
Only a few studies evaluated the RV systolic function in the three categories of HF, regarding the importance of understanding changes in RV function on clinical presentation and outcome; it was essential to understand the…
- Trial name
- NCT03641599
- Testing
- echocardiography
- Volunteers
- 150 people
- Sponsor
- shaimaa Mostafa
Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction (HFrEF and HFmrEF)
Polypharmacy, Safety, and Medication Adherence in Patients With Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction
This prospective registry study (FARAON) aims to assess the prevalence, structure, safety profile, and dynamics of polypharmacy, as well as its association with medication adherence, quality of life, and clinical outcomes in…
- Trial name
- FARAON (NCT07640854)
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
- Trial name
- PANTHEON (NCT02992288)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 75 sites in United States, Belgium and 9 more
- Volunteers
- 427 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive…
- Trial name
- NCT02389933
- Testing
- LCZ696
- Where
- 286 sites in United States, Australia and 16 more
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Heart Failure
Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF
Atrial fibrillation (AF) is the most common arrhythmia, accounting for one third of all hospital admissions and 1% of all emergency department visits (ED). Approximately 65% of those presenting to the ED with AF are admitted.
- Trial name
- NCT02938260
- Testing
- Metoprolol vs Diltiazem
- Volunteers
- 48 people
- Sponsor
- RaeAnn Hirschy
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of age or older, who have symptomatic heart failure with preserved ejection fraction…
- Trial name
- FROST-HF (NCT05136820)
- Testing
- Atrial Flow Regulator
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Occlutech International AB
Heart Failure With Reduced Ejection Fraction
Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure
The main aim of this study is to investigate the effect of melatonin on clinical outcome, quality of life, and cardiovascular function of the patients with heart failure, as well as its effect on their skeletal muscle mass and…
- Trial name
- NCT03894683
- Testing
- Melatonin 10 mg
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Isfahan University of Medical Sciences
Heart Failure With Reduced Ejection Fraction, Renal Insufficiency
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
Heart Failure (HF) poses a major health burden in various populations, with devastating annual rates of morbidity and mortality. It is estimated that 1%-to-2% of the general population suffer from the heart failure syndrome.
- Trial name
- TRIUMF (NCT04736329)
- Testing
- Telmisartan
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Cairo University
Heart Failure, Heart Failure, Systolic
Short-Term Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy
This prospective cohort study aims to evaluate short-term (3-month) clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical…
- Trial name
- NCT07821801
- Volunteers
- 250 people
- Sponsor
- Assiut University
Heart Failure NYHA Class III
Optimizing HFrEF Patients Using BaroStim and CardioMems
The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device.
- Trial name
- NCT07399587
- Testing
- BaroStim
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwell Health
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Exercise Training
Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency
It is the aim of the study to prove, if intravenous supplementation with ferric carboxymaltose in iron-deficient patients with heart failure with reduced ejection fraction (HFrEF) leads to better exercise training effects…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Exercise Training, Ferric Carboxymaltose
- Trial name
- IronEx (NCT03803111)
- Testing
- Initial exercise training, Initial FCM, Subsequent FCM
- Where
- Germany
- Sponsor
- Herzzentrum Bremen